Table 2 Adverse events characteristics
Variables | Group LN (n = 385) | Group OVW (n = 501) | Group OBS (n = 120) | P |
|---|---|---|---|---|
Mortality and morbidities | 6 (2.2) | 12 (2.5) | 8 (3.2) | 0.735 |
Mortality | 1 (0.4) | 0 (0.0) | 0 (0.0) | 0.523 |
Any morbidity | 5 (1.8) | 12 (2.5) | 8 (3.2) | 0.588 |
Cardiac arrest | 1 (0.4) | 2 (0.4) | 0 (0.0) | 0.804 |
Atrial fibrillation | 1 (0.4) | 4 (0.8) | 4 (1.6) | 0.338 |
New pacemaker | 3 (1.1) | 2 (0.4) | 2 (0.8) | 0.486 |
Non-fatal myocardial infarction | 0 (0.0) | 2 (0.4) | 1 (0.4) | 0.616 |
Low cardiac output | 4 (1.4) | 7 (1.5) | 3 (1.2) | 1 |
Intra-aortic balloon pump | 1 (0.4) | 4 (0.8) | 0 (0.0) | 0.525 |
Extracorporeal membrane oxygenation | 4 (1.4) | 10 (2.1) | 3 (1.2) | 0.700 |
Non-fatal stroke | 0 (0.0) | 2 (0.4) | 3 (1.2) | 0.120 |
Continuous renal replacement therapy | 7 (2.5) | 15 (3.1) | 6 (2.4) | 0.803 |
Pneumonia | 151 (54.5) | 265 (55.2) | 129 (51.8) | 0.683 |